625389-73-3

Upstream product

• 625389-74-4 (1S,2R)-1-(tert-butyldiphenylsilyloxy)methyl-2-formyl-2-phenylcyclopropane 
• 96847-52-8 (1R,2S)-2-oxo-1-phenyl-3-oxabicyclo[3.1.0]hexane 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 625389-71-1 (+)-(1R,2S)-(2-hydroxymethyl-1-phenyl-cyclopropyl)-methanol 

Downstream Products

• 625389-74-4 (1S,2R)-1-(tert-butyldiphenylsilyloxy)methyl-2-formyl-2-phenylcyclopropane 
• 1075720-77-2 C₂₇H₃₁BrOSi 
• 625389-75-5 (1R,2S)-2-((tert-butyldiphenylsilyloxy)methyl)-1-phenylcyclopropanecarboxylic acid 
• 29667-46-7 (1S,2R)-2-phenylcyclopropylmethanol 
• 110659-58-0 (1S,2S)-trans-1-(hydroxymethyl)-2-phenylcyclopropane 

Relevant academic research and scientific papers

Synthesis of 1-arylpiperazyl-2-phenylcyclopropanes designed as antidopaminergic agents: Cyclopropane-based conformationally restricted analogs of haloperidol

A series of the cyclopropane-based conformationally restricted analogs of haloperidol were designed as potential antidopaminergic agents and were effectively synthesized using highly stereoselective Grignard reaction with tert-butanesulfinyl imines as the key step. Pharmacological evaluation of the compounds showed that the conformational restriction method can effectively work for improving the pharmacological selectivity of a parent compound and also for investigating the bioactive conformation.

Construction of a cis-Cyclopropane via Reductive Radical Decarboxylation. Enantioselective Synthesis of cis- and trans-1-Arylpiperazyl-2-phenylcyclopropanes Designed as Antidopaminergic Agents

(1S,2S)-, (1S,2R)-, and (1R,2S)-1-(2,4-Dimethylphenyl)piperazyl-2-phenylcyclopropane (2a, 3, and ent-3, respectively), which were designed as conformationally restricted analogues of haloperidol (1), a clinically effective antipsychotic agent, were synthe